Sensyne chairman stands down following Downing Street appointment

Newly listed clinical AI tech company Sensyne Health's chairman John Bell stepped down as chairman of the board on Wednesday.

Sensyne told investors that Bell had opted to walk away from the AIM-quoted outfit in order to avoid any potential conflicts of interest that could arise as a result of his work with Downing Street on the government's life sciences industrial strategy.

Bell, who authored the government's life sciences strategy document, has been instrumental in delivering a programme defined in the report to grow the life sciences sector in the UK.

Sensyne will replace Bell with Charles Swingland on an interim basis. Swingland will return to his post as a non-executive director when Sensyne's search for a permanent chairman is complete.

Bell said: "I have thoroughly enjoyed my time at Sensyne, supporting the business through its initial development and recent successes. Now is the right time to relinquish my Board responsibilities to avoid any potential conflicts of interest."

As of 0835 BST, Sensyne shares had slipped 2.05% to 191p.